Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 1.11B | 11.1% |
| Gross Profit | 695M | 11.4% |
| Cost of Revenue | 415M | 10.6% |
| Operating expense | 322M | 4.8% |
| Net Income | 294M | 21.1% |
| EBITDA | 409M | 16.4% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 3.33B | 3.6% |
| Total Liabilities | 1.87B | 6% |
| Total Equity | 1.46B | 0.7% |
| Shares Outstanding | 81M | 1.1% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | 186M | 21.9% |
| Cash from investing | -34M | 13.6% |
| Cash from financing | -166M | 49.9% |
EPS
Financial Highlights for Idexx Laboratories in Q2 '25
Idexx Laboratories reported a revenue of 1.11B, which is a 11.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 695M, marking a 11.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 415M, a 10.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 322M, showing a 4.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 294M, showing a 21.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 409M, showing a 16.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Idexx Laboratories with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
